| Literature DB >> 29807932 |
Lígia C Gomes-da-Silva1,2,3,4, Liwei Zhao2,3,4, Lucillia Bezu2,3,4, Heng Zhou2,3,4, Allan Sauvat2,3,4, Peng Liu2,3,4, Sylvère Durand3,4, Marion Leduc2,3,4, Sylvie Souquere5,6, Friedemann Loos2,3,4, Laura Mondragón2,3,4, Baldur Sveinbjørnsson7,8, Øystein Rekdal7,8, Gaelle Boncompain9, Franck Perez9, Luis G Arnaut1, Oliver Kepp10,3,4, Guido Kroemer10,3,4,11,12,13,14.
Abstract
Preclinical evidence depicts the capacity of redaporfin (Redp) to act as potent photosensitizer, causing direct antineoplastic effects as well as indirect immune-dependent destruction of malignant lesions. Here, we investigated the mechanisms through which photodynamic therapy (PDT) with redaporfin kills cancer cells. Subcellular localization and fractionation studies based on the physicochemical properties of redaporfin revealed its selective tropism for the endoplasmic reticulum (ER) and the Golgi apparatus (GA). When activated, redaporfin caused rapid reactive oxygen species-dependent perturbation of ER/GA compartments, coupled to ER stress and an inhibition of the GA-dependent secretory pathway. This led to a general inhibition of protein secretion by PDT-treated cancer cells. The ER/GA play a role upstream of mitochondria in the lethal signaling pathway triggered by redaporfin-based PDT Pharmacological perturbation of GA function or homeostasis reduces mitochondrial permeabilization. In contrast, removal of the pro-apoptotic multidomain proteins BAX and BAK or pretreatment with protease inhibitors reduced cell killing, yet left the GA perturbation unaffected. Altogether, these results point to the capacity of redaporfin to kill tumor cells via destroying ER/GA function.Entities:
Keywords: Golgi apparatus; Golgi‐targeting agents; photodynamic therapy; redaporfin; retrograde transport
Mesh:
Substances:
Year: 2018 PMID: 29807932 PMCID: PMC6028029 DOI: 10.15252/embj.201798354
Source DB: PubMed Journal: EMBO J ISSN: 0261-4189 Impact factor: 11.598